Avidity Biosciences, Inc. (RNA)

NASDAQ: RNA · IEX Real-Time Price · USD
14.22 -0.48 (-3.27%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap666.88M
Revenue (ttm)9.62M
Net Income (ttm)-95.75M
Shares Out46.90M
EPS (ttm)-2.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume322,154
Open14.49
Previous Close14.70
Day's Range14.10 - 15.44
52-Week Range14.10 - 29.59
Betan/a
AnalystsStrong Buy
Price Target49.80 (+250.2%)
Earnings Daten/a

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable...

IndustryBiotechnology
IPO DateJun 12, 2020
Employees71
Stock ExchangeNASDAQ
Ticker SymbolRNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is 49.80, which is an increase of 250.21% from the latest price.

Price Target
$49.80
(250.21% upside)
Analyst Consensus: Strong Buy

News

Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event

LA JOLLA, Calif., Dec. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...

1 month ago - PRNewsWire

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st...

2 months ago - Zacks Investment Research

Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

LA JOLLA, Calif., Nov. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...

2 months ago - PRNewsWire

Earnings Preview: Avidity Biosciences, Inc. (RNA) Q3 Earnings Expected to Decline

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Avidity Biosciences to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

2 months ago - PRNewsWire

Avidity Biosciences Announces Changes to its Board of Directors

LA JOLLA, Calif., Aug. 25, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...

4 months ago - PRNewsWire

Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers f...

LA JOLLA, Calif., Aug. 16, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleoti...

5 months ago - PRNewsWire

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 9.09% and 73.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

LA JOLLA, Calif., Aug. 9, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...

5 months ago - PRNewsWire

Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif., Aug. 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...

5 months ago - PRNewsWire

Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif., Aug. 2, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotid...

5 months ago - PRNewsWire

Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle Wasting Disorder

The FDA has signed off Avidity Biosciences Inc's (NASDAQ: RNA) Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1). Myotonic dystrophy is characterized by progressive muscl...

5 months ago - Benzinga

Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event

LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleot...

8 months ago - PRNewsWire

Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

LA JOLLA, Calif., May 12, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleot...

8 months ago - PRNewsWire

Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021

LA JOLLA, Calif., May 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleoti...

8 months ago - PRNewsWire

Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights

LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

10 months ago - PRNewsWire

Biotech Shares Have Soared Since 2020's Wave of IPOs

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other symbols:AVIRJNJLEGNLLYNKTX
11 months ago - GuruFocus

Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

1 year ago - PRNewsWire

Avidity Biosciences Announces Addition to the Nasdaq Biotechnology Index

LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

1 year ago - PRNewsWire

Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights

LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleo...

1 year ago - PRNewsWire

Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020

LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucle...

1 year ago - PRNewsWire

Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

1 year ago - PRNewsWire

Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

1 year ago - PRNewsWire

Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer

SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Co...

1 year ago - PRNewsWire